Literature DB >> 18050250

Endothelin is a downstream mediator of profibrotic responses to transforming growth factor beta in human lung fibroblasts.

Xu Shi-wen1, Laura Kennedy, Elisabetta A Renzoni, George Bou-Gharios, Roland M du Bois, Carol M Black, Christopher P Denton, David J Abraham, Andrew Leask.   

Abstract

OBJECTIVE: Fibrosis is excessive scarring caused by the accumulation and contraction of extracellular matrix proteins and is a common end pathway in many chronic diseases, including scleroderma (systemic sclerosis [SSc]). Indeed, pulmonary fibrosis is a major cause of death in SSc. Transforming growth factor beta (TGFbeta) induces endothelin 1 (ET-1) in human lung fibroblasts by a Smad-independent, JNK-dependent mechanism. The goal of this study was to assess whether ET-1 is a downstream mediator of the profibrotic effects of TGFbeta in lung fibroblasts.
METHODS: We used a specific endothelin receptor antagonist to determine whether ET-1 is a downstream mediator of TGFbeta responses in lung fibroblasts, using microarray technology, real-time polymerase chain reaction, and Western blot analyses.
RESULTS: The ability of TGFbeta to induce the expression of a cohort of profibrotic genes, including type I collagen, fibronectin, and CCN2, and to contract a collagen gel matrix, depends on ET-1.
CONCLUSION: ET-1 contributes to the ability of TGFbeta to promote a profibrotic phenotype in human lung fibroblasts, consistent with the notion that endothelin receptor antagonism may be beneficial in controlling fibrogenic responses in lung fibroblasts.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18050250     DOI: 10.1002/art.23134

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  63 in total

1.  Survivin expression induced by endothelin-1 promotes myofibroblast resistance to apoptosis.

Authors:  Jeffrey C Horowitz; Iyabode O Ajayi; Priya Kulasekaran; David S Rogers; Joshua B White; Sarah K Townsend; Eric S White; Richard S Nho; Peter D R Higgins; Steven K Huang; Thomas H Sisson
Journal:  Int J Biochem Cell Biol       Date:  2011-10-25       Impact factor: 5.085

Review 2.  Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities.

Authors:  Swati Bhattacharyya; Jun Wei; John Varga
Journal:  Nat Rev Rheumatol       Date:  2011-10-25       Impact factor: 20.543

3.  Transforming growth factor-β regulates endothelin-1 signaling in the newborn mouse lung during hypoxia exposure.

Authors:  Nelida Olave; Teodora Nicola; Wei Zhang; Arlene Bulger; Masheika James; Suzanne Oparil; Yiu-Fai Chen; Namasivayam Ambalavanan
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-01-27       Impact factor: 5.464

Review 4.  Recent advances in the treatment of systemic sclerosis.

Authors:  Vasiliki Kalliopi K Bournia; Panayiotis G Vlachoyiannopoulos; Carlo Selmi; Haralampos M Moutsopoulos; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

5.  CCN2: a bona fide target for anti-fibrotic drug intervention.

Authors:  Andrew Leask
Journal:  J Cell Commun Signal       Date:  2011-03-06       Impact factor: 5.782

Review 6.  Transient receptor potential (TRP) channels and cardiac fibrosis.

Authors:  Zhichao Yue; Yanhui Zhang; Jia Xie; Jianmin Jiang; Lixia Yue
Journal:  Curr Top Med Chem       Date:  2013       Impact factor: 3.295

7.  Endothelin-1 and transforming growth factor-beta1 independently induce fibroblast resistance to apoptosis via AKT activation.

Authors:  Priya Kulasekaran; Casey A Scavone; David S Rogers; Douglas A Arenberg; Victor J Thannickal; Jeffrey C Horowitz
Journal:  Am J Respir Cell Mol Biol       Date:  2009-02-02       Impact factor: 6.914

8.  Towards an anti-fibrotic therapy for scleroderma: targeting myofibroblast differentiation and recruitment.

Authors:  Andrew Leask
Journal:  Fibrogenesis Tissue Repair       Date:  2010-05-27

9.  Systemic vasculopathy with altered vasoreactivity in a transgenic mouse model of scleroderma.

Authors:  Emma C Derrett-Smith; Audrey Dooley; Korsa Khan; Xu Shi-wen; David Abraham; Christopher P Denton
Journal:  Arthritis Res Ther       Date:  2010-04-15       Impact factor: 5.156

10.  Connective tissue growth factor (CTGF, CCN2) gene regulation: a potent clinical bio-marker of fibroproliferative disease?

Authors:  Andrew Leask; Sunil K Parapuram; Xu Shi-Wen; D J Abraham
Journal:  J Cell Commun Signal       Date:  2009-01-21       Impact factor: 5.782

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.